Global Markets Direct’s, 'Nosocomial Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Nosocomial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nosocomial Infections. Nosocomial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Nosocomial Infections. - A review of the Nosocomial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Nosocomial Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Nosocomial Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Nosocomial Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Nosocomial Infections - Pipeline Review, H2 2013 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Nosocomial Infections Overview 8 Therapeutics Development 9 An Overview of Pipeline Products for Nosocomial Infections 9 Nosocomial Infections Therapeutics under Development by Companies 11 Nosocomial Infections Therapeutics under Investigation by Universities/Institutes 13 Discovery and Pre-Clinical Stage Products 14 Comparative Analysis 14 Nosocomial Infections Therapeutics - Products under Development by Companies 15 Nosocomial Infections Therapeutics - Products under Investigation by Universities/Institutes 16 Companies Involved in Nosocomial Infections Therapeutics Development 17 Pfizer Inc. 17 Paratek Pharmaceuticals, Inc. 18 Achaogen Inc. 19 Immupharma Plc 20 Priaxon AG 21 MAT Biopharma 22 Amura Holdings Ltd. 23 Integrated BioTherapeutics, Inc. 24 AIMM Therapeutics B.V. 25 SelectX Pharmaceuticals, Inc. 26 Cantab Biopharmaceuticals Limited 27 Agennix AG 28 Da Volterra 29 Nosocomial Infections - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 NVB-333 - Drug Profile 35 Product Description 35 Mechanism of Action 35 RandD Progress 35 AM-112 - Drug Profile 36 Product Description 36 Mechanism of Action 36 RandD Progress 36 MAR Program - Drug Profile 37 Product Description 37 Mechanism of Action 37 RandD Progress 37 IPP-203101 - Drug Profile 38 Product Description 38 Mechanism of Action 38 RandD Progress 38 MAT-401 - Drug Profile 39 Product Description 39 Mechanism of Action 39 RandD Progress 39 Hybrid Antibiotics - Drug Profile 40 Product Description 40 Mechanism of Action 40 RandD Progress 40 Multivalent Staph Vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 RandD Progress 41 ACHN-978 - Drug Profile 42 Product Description 42 Mechanism of Action 42 RandD Progress 42 Clostridium Dificile Program - Drug Profile 43 Product Description 43 Mechanism of Action 43 RandD Progress 43 SXP-2523 - Drug Profile 44 Product Description 44 Mechanism of Action 44 RandD Progress 44 DAV-132 - Drug Profile 45 Product Description 45 Mechanism of Action 45 RandD Progress 45 DAV-148 - Drug Profile 46 Product Description 46 Mechanism of Action 46 RandD Progress 46 Enoyl Reductase Inhibitors - Drug Profile 47 Product Description 47 Mechanism of Action 47 RandD Progress 47 BVNC-1 - Drug Profile 48 Product Description 48 Mechanism of Action 48 RandD Progress 48 BVNC-2 - Drug Profile 49 Product Description 49 Mechanism of Action 49 RandD Progress 49 Dap-3 Polymyxin Analogs - Drug Profile 50 Product Description 50 Mechanism of Action 50 RandD Progress 50 Monoclonal Antibody Therapeutics Program For Nosocomial Infections - Drug Profile 51 Product Description 51 Mechanism of Action 51 RandD Progress 51 TP-112 - Drug Profile 52 Product Description 52 Mechanism of Action 52 RandD Progress 52 TP-106 - Drug Profile 53 Product Description 53 Mechanism of Action 53 RandD Progress 53 TP-107 - Drug Profile 54 Product Description 54 Mechanism of Action 54 RandD Progress 54 Nosocomial Infections Therapeutics - Drug Profile Updates 55 Nosocomial Infections Therapeutics - Dormant Products 56 Nosocomial Infections - Product Development Milestones 57 Featured News and Press Releases 57 Sep 07, 2012: Kalidex Pharma To Present Clinical Data On Next-generation Fluoroquinolone KPI-10 At ICAAC 2012 57 May 07, 2012: Integrated BioTherapeutics Receives $600,000 Phase I SBIR Grant For Novel Staph Vaccine 58 Mar 18, 2010: Achillion Announces Award Of NIH Grant To Study Unique Antibacterial Compound Series 58 Jan 28, 2010: Theravance Receives Response Letter From FDA For Telavancin NDA For The Treatment Of Nosocomial Pneumonia 59 Dec 14, 2009: Cubist Pharmaceuticals To Acquire Calixa Therapeutics 60 Nov 30, 2009: Theravance Announces The Completion Of Validation Phase Of Telavancin MAA By The EMEA 61 Oct 07, 2008: Novacta Therapeutics Achieves First Milestone From The Wellcome Trust's Strategic Translational Award For NVB302, A New Treatment For C. difficile Infection 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 63 Disclaimer 63
List of Tables
Number of Products Under Development for Nosocomial Infections, H2 2013 9 Products under Development for Nosocomial Infections - Comparative Analysis, H2 2013 10 Number of Products under Development by Companies, H2 2013 12 Number of Products under Investigation by Universities/Institutes, H2 2013 13 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14 Products under Development by Companies, H2 2013 15 Products under Investigation by Universities/Institutes, H2 2013 16 Pfizer Inc., H2 2013 17 Paratek Pharmaceuticals, Inc., H2 2013 18 Achaogen Inc., H2 2013 19 Immupharma Plc, H2 2013 20 Priaxon AG, H2 2013 21 MAT Biopharma, H2 2013 22 Amura Holdings Ltd., H2 2013 23 Integrated BioTherapeutics, Inc., H2 2013 24 AIMM Therapeutics B.V., H2 2013 25 SelectX Pharmaceuticals, Inc., H2 2013 26 Cantab Biopharmaceuticals Limited, H2 2013 27 Agennix AG, H2 2013 28 Da Volterra, H2 2013 29 Assessment by Monotherapy Products, H2 2013 30 Assessment by Stage and Route of Administration, H2 2013 32 Assessment by Stage and Molecule Type, H2 2013 34 Nosocomial Infections Therapeutics - Drug Profile Updates 55 Nosocomial Infections Therapeutics - Dormant Products 56
List of Figures
Number of Products under Development for Nosocomial Infections, H2 2013 9 Products under Development for Nosocomial Infections - Comparative Analysis, H2 2013 10 Products under Development by Companies, H2 2013 11 Products under Investigation by Universities/Institutes, H2 2013 13 Discovery and Pre-Clinical Stage Products, H2 2013 14 Assessment by Monotherapy Products, H2 2013 30 Assessment by Route of Administration, H2 2013 31 Assessment by Stage and Route of Administration, H2 2013 32 Assessment by Molecule Type, H2 2013 33 Assessment by Stage and Molecule Type, H2 2013 34
Pfizer Inc. Paratek Pharmaceuticals, Inc. Achaogen Inc. Immupharma Plc Priaxon AG MAT Biopharma Amura Holdings Ltd. Integrated BioTherapeutics, Inc. AIMM Therapeutics B.V. SelectX Pharmaceuticals, Inc. Cantab Biopharmaceuticals Limited Agennix AG Da Volterra